AI assistant
Sending…
BIO-RAD LABORATORIES, INC. — Director's Dealing 2019
Sep 5, 2019
30786_dirs_2019-09-05_c1680754-07a2-4491-b038-423d351ba625.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-RAD LABORATORIES, INC. (BIO, BIOB)
CIK: 0000012208
Period of Report: 2019-09-03
Reporting Person: TUMOLO ANNETTE (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-09-04 | Bio-Rad A Common Stock | M | 600 | — | Acquired | 2104.3476 | Direct |
| 2019-09-04 | Bio-Rad A Common Stock | F | 208 | $335.20 | Disposed | 1896.3476 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-09-03 | Restricted Stock Units | $0 | A | 2784 | Acquired | Bio-Rad A Common Stock (2784) | Direct | |
| 2019-09-03 | Non-Qualified Stock Option (right to buy) | $333.34 | A | 2784 | Acquired | 2029-09-03 | Bio-Rad A Common Stock (2784) | Direct |
| 2019-09-04 | Restricted Stock Units | $0 | M | 600 | Disposed | Bio-Rad A Common Stock (600) | Direct |
Footnotes
F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F3: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant.
F4: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant.
F5: The restricted stock units vest in five equal annual installments beginning September 4, 2019.
More from BIO-RAD LABORATORIES, INC.
Regulatory Filings
2026
May 13
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Annual Report
2026
Mar 25
Proxy Solicitation & Information Statement
2026
Mar 25
Regulatory Filings
2026
Feb 19
Annual Report
2026
Feb 13